CSL Limited Sponsored ADR (OTCMKTS:CSLLY) Short Interest Update

Key Points

• CSL Limited Sponsored ADR (OTCMKTS:CSLLY) experienced a substantial increase in short interest, rising by 164.6% in July to a total of 20,900 shares.
• The company's current stock price is $87.86, with its 12-month low and high at $70.22 and $109.00 respectively.
• CSL operates in the biopharmaceutical industry, providing products through segments such as CSL Behring and CSL Seqirus, focusing on plasma products, gene therapies, and vaccines.

CSL Limited Sponsored ADR (OTCMKTS:CSLLY - ) saw a significant increase in short interest in the month of July. As of July 31st, there was short interest totaling 20,900 shares, anincreaseof164.6% from the July 15th total of 7,900 shares. Currently,0.0% of the company's stock are short sold. Based on an average daily trading volume, of 107,500 shares, the short-interest ratio is currently 0.2 days. Based on an average daily trading volume, of 107,500 shares, the short-interest ratio is currently 0.2 days. Currently,0.0% of the company's stock are short sold.

CSL Stock Performance

CSL stock opened at $87.86 on Friday. The business has a fifty day moving average of $82.50 and a two-hundred day moving average of $80.69. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.85 and a current ratio of 1.86. CSL has a twelve month low of $70.22 and a twelve month high of $109.00.

CSL Company Profile

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.